[en] Biologicals have become an important component in the treatment of Crohn's disease in children. Their increased and long term use raises safety concerns. We describe safety and cost of infliximab in Belgian pediatric Crohn's disease patients. All patients on infliximab as part of the present or past treatment for Crohn's Disease until January 1st 2011 were selected from an existing database. Information on disease phenotype, medication and adverse events were extracted. Adverse events occurred in 25.9% of patients exposed to infliximab of which 29.6% were severe. In total 31.7% of patients stopped infliximab therapy. The main reasons for discontinuation were adverse events in 45.4% and loss of response in 30.3%. No malignancies or lethal complications occurred over this 241 patient year observation period. Immunomodulators were concomitant medication in 75% of patients and were discontinued subsequently in 38.4% of them. The cost of infliximab infusions per treated patient per year in the Belgian health care setting is approximately 9 474 euro, including only medication and hospital related costs. Even though infliximab is relatively safe in pediatric CD on the short term, close follow-up and an increased awareness of the possible adverse reactions is highly recommended. Adverse reactions appeared in 25.9% of all patients and were the main reason for discontinuation. Treatment cost has to be balanced against efficacy and modifications in disease course. In the Belgian health care system, the medication is available to all patients with moderate to severe CD.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
De Greef, E.
Hoffman, I.
D'Haens, G.
Van Biervliet, S.
Smets, F.
Scaillon, M.
Dewit, O
Peeters, H.
Paquot, I.
Alliet, P.
Arts, W.
Hauser, B.
Vermeire, S.
Van Gossum, A.
Rahier, Jean-François
Etienne, I.
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Coche, J. C.
Mahachie John, Jestinah ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
BENCHIMOL E.I., FORTINSKY K.J., GOZDYRA P. et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflammatory bowel diseases, 2010, 17: 423-439.
HANAUER S.B., FEAGAN B.G., LICHTENSTEIN G.R. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359: 1541-1549.
HYAMS J., CRANDALL W., KUGATHASAN S. et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology, 2007, 132: 863-873, quiz 1165-1166.
LICHTENSTEIN G.R., FEAGAN B.G., COHEN R.D. et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol., 2006, 4: 621-630.
BEAUGERIE L., BROUSSE N., BOUVIER A.M. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, 2009, 374: 1617-1625.
ROSH J.R., GROSS T., MAMULA P. et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflammatory bowel diseases, 2007, 13: 1024-1030.
HYAMS J.S., LERER T., GRIFFITHS A. et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflammatory bowel diseases, 2009, 15: 816-822.
HYAMS J., WALTERS T.D., CRANDALL W. et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Current medical research and opinion, 2011, 27: 651-662.
CROMBE V., SALLERON J., SAVOYE G. et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: A populationbased study. Inflammatory bowel diseases, 2011.
RUEMMELE F.M., LACHAUX A., CEZARD J.P. et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflammatory bowel diseases, 2009, 15: 388-394.
Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J. Pediatr. Gastroenterol. Nutr., 2005, 41: 1-7.
SILVERBERG M.S., SATSANGI J., AHMAD T. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the, 2005 Montreal World Congress of Gastroenterology. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2005, 19 Suppl A: 5-36.
LEVINE A., GRIFFITHS A., MARKOWITZ J. et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification. Inflammatory bowel diseases, 2010.
BORRELLI O., BASCIETTO C., VIOLA F. et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis., 2004, 36: 342-347.
WALTERS T.D., GILMAN A.R., GRIFFITHS A.M. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflammatory bowel diseases, 2007, 13: 424-430.
MACKEY A.C., GREEN L., LIANG L.C. et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr., 2007, 44: 265-267.
D'HAENS G.R., PANACCIONE R., HIGGINS P.D. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? The American journal of gastroenterology, 2011, 106: 199-212, quiz 213.
WYNANDS J., BELBOUAB R., CANDON S. et al. 12-month follow-up after successful infliximab therapy in pediatric crohn disease. J. Pediatr. Gastroenterol. Nutr., 2008, 46: 293-298.
DRETZKE J., EDLIN R., ROUND J., CONNOCK M., HULME C., CZECZOT J., FRY-SMITH A., MC CABE C., MEADS C. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technology Assessment, 2011, 15: 1-244.
BODGER K., KIKUCHI T., HUGHES D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Alimentary pharmacology & therapeutics, 2009, 30: 265-274.
KAY M., WYLLIE R. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD. The American journal of gastro-enterology, 2003, 98: 717-720.
PUNEKAR YS., SUNDERLAND T., HAWKINS N. et al. Cost-effectiveness of scheduled maintenance treatment with infliximab for pediatric Crohn's disease. Value Health, 2010, 13: 188-195.